Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Baloxavir marboxil tablets (adults at least 40 kg) - selected U.S. labeling
Product / population
Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.
Renal method
CrCl mL/min describes study evidence, not a severe-renal dose rule.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Official
Baloxavir marboxil tablets (adults at least 40 kg) - selected U.S. labeling
U.S. product labeling / DailyMed · Adults weighing at least 40 kg with acute uncomplicated influenza; oral baloxavir tablets. Pediatric and liquid formulations are outside this summary.
Renal method: CrCl mL/min describes study evidence, not a severe-renal dose rule. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
Give a single oral dose within 48 hours of symptom onset: 40 mg for weight 40 to less than 80 kg, or 80 mg for weight at least 80 kg.
No clinically meaningful pharmacokinetic difference was seen at CrCl 50 mL/min or greater. Severe-renal pharmacokinetics have not been evaluated; this label does not establish a numeric severe-renal or dialysis adjustment.
RDM31-baloxavir-label-renal · Source locator: 12.3: Specific Populations
Selected warnings and limits
Avoid coadministration with dairy/calcium-fortified drinks and polyvalent-cation antacids, laxatives or supplements because absorption may fall.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.